Alprostadil

證據等級: L5

預測適應症: 10 個

Alprostadil: From Duct-Dependent Congenital Heart Disease to Aortic Malformation

One-Sentence Summary

Alprostadil (prostaglandin E1) is a potent vasodilator used to maintain ductus arteriosus patency in neonates with duct-dependent congenital heart disease, as well as for peripheral arterial occlusive disease and erectile dysfunction. The TxGNN model predicts it may be effective for Aortic Malformation, with 2 clinical trials and 20 publications currently supporting this direction. Notably, the majority of TxGNN’s top-10 predictions cluster around congenital heart defects, reinforcing the biological coherence of these predictions.

Quick Overview

Item	Content
Original Indication	Duct-dependent congenital heart disease (maintaining ductus arteriosus patency), peripheral arterial occlusive disease, erectile dysfunction
Predicted New Indication	Aortic Malformation
TxGNN Prediction Score	99.98%
Evidence Level	L3 — Observational studies and clinical case series
NL Market Status	Not marketed (no CBG-MEB authorizations identified in this evidence pack)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Alprostadil is the synthetic form of prostaglandin E1 (PGE1). It acts directly on EP receptors on the smooth muscle of the ductus arteriosus, preventing ductal constriction and maintaining patency. Additionally, PGE1 is a potent vasodilator that increases blood flow in the pulmonary and systemic circulations. Since the late 1970s, PGE1 infusion has been the cornerstone of initial medical management for neonates born with duct-dependent cardiac lesions, buying critical time before surgical intervention.

Aortic malformations — including interrupted aortic arch, aortic atresia, critical aortic stenosis, and coarctation of the aorta — are classic examples of duct-dependent systemic circulation lesions. In these conditions, the descending aorta receives its blood supply through a patent ductus arteriosus. Without PGE1 to maintain ductal patency, systemic perfusion collapses, leading to metabolic acidosis, organ failure, and death. The literature confirms that PGE1 introduction in the late 1970s “revolutionized the management of interrupted aortic arch” (Jonas, 2015).

The TxGNN prediction is therefore highly mechanistically coherent. In fact, the use of alprostadil for aortic malformations is already well-established clinical practice in neonatal cardiology worldwide, although it may not appear as a specifically labelled indication in all regulatory jurisdictions. This represents a case where TxGNN has independently rediscovered an established off-label use through knowledge graph analysis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04054115	Phase 1	Terminated	10	Studied acute effects of alprostadil on cerebral and pulmonary blood flow after bidirectional cavopulmonary connection (Glenn procedure). Confirmed clinical interest in PGE1 haemodynamic effects in congenital heart disease. Limited conclusions due to early termination.
NCT02042092	N/A	Completed	39	Cross-sectional imaging comparison (CDUS vs MRA) in large vessel vasculitis involving the aorta. Not a drug treatment trial; relevance limited to overlapping patient population with aortic pathology.

Note: The limited number of registered clinical trials reflects the fact that PGE1 use in duct-dependent aortic malformations is already accepted standard of care rather than an experimental intervention, reducing the need for prospective trials.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26686446	2015	Review	Semin Thorac Cardiovasc Surg	PGE1 introduction in the late 1970s revolutionized management of interrupted aortic arch. Direct arch anastomosis with VSD closure is preferred.
6763200	1982	Clinical series	Pharmacotherapy	Landmark evaluation of alprostadil in congenital heart disease. PGE1 dilates ductus, increases pulmonary blood flow, and improves systemic perfusion in aortic arch obstruction.
16368373	2006	Retrospective	Ann Thorac Surg	Outcomes of closed transventricular aortic valvotomy for critical neonatal aortic stenosis. PGE1 used as preoperative stabilization.
25647388	2014	Review	Cardiol Young	Preoperative management of critical aortic stenosis in neonates. PGE1 infusion is essential for haemodynamic stabilization before intervention.
19080093	2008	Clinical study	Zhonghua Yi Xue Za Zhi	Alprostadil (Lipo-PGE1) and ulinastatin attenuate inflammatory response and lung injury after CPB in paediatric congenital heart disease.
32184038	2020	Retrospective	Asian J Surg	Staged surgical repair for interrupted aortic arch. PGE1 used for preoperative ductal maintenance.
7201134	1982	Case series	Pediatr Cardiol	PGE1 infusion in 7 infants with hypoplastic left ventricle and aortic atresia. Transient metabolic and circulatory improvement demonstrated.
6537955	1984	Case series	J Am Coll Cardiol	Long-term PGE1 therapy (avg 39 days) in 17 neonates with congenital heart defects including aortic coarctation.
30347623	2019	Retrospective	J Neonatal Perinatal Med	Enteral feeding strategies in duct-dependent congenital heart disease patients on PGE1 infusion.
1926911	1991	Review	DICP Ann Pharmacother	PGE1 use prior to neonatal transport for suspected duct-dependent cardiac defects. Recommends early stabilization with PGE1.

Netherlands Market Information

No CBG-MEB marketing authorizations for alprostadil were identified in this evidence pack. However, alprostadil is available in many EU member states under various brand names (e.g., Prostin VR for neonatal use, Caverject for erectile dysfunction, Alprostadil Alfadex for peripheral arterial disease). A search of the CBG-MEB Geneesmiddeleninformatiebank and/or the EMA centralized register is recommended to confirm current Dutch market availability.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for comprehensive safety information.

Known safety profile from literature (for clinical context):

Alprostadil (PGE1) has a well-characterized safety profile from decades of clinical use in neonatal cardiology. Commonly reported adverse effects include:

Apnoea (10–12% of neonates; ventilatory support should be immediately available)
Fever, flushing, and bradycardia
Hypertrophic pyloric stenosis with prolonged use (>5 days)
Cortical bone proliferation with prolonged use
Hypotension (dose-dependent vasodilatory effect)

Detailed warnings, contraindications, and drug interaction data were not available in this evidence pack. The treating physician should consult the relevant SmPC before use.

Additional Predicted Indications

The TxGNN model predicted multiple congenital heart defects for alprostadil. The table below summarizes all predictions for a comprehensive view:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Aortic malformation	99.98%	L3	Proceed with Guardrails
2	Congenital tricuspid stenosis	99.94%	L4	Proceed with Guardrails
3	Congenital valvular dysplasia	99.93%	L5	Hold
4	Straddling/overriding tricuspid valve	99.93%	L5	Research Question
5	Tricuspid valve agenesis	99.93%	L4	Proceed with Guardrails
6	Tricuspid valve prolapse	99.92%	L5	Hold
7	Anomaly of tricuspid subvalvular apparatus	99.92%	L5	Hold
8	DORV with AVSD, PS, heterotaxy	99.91%	L5	Research Question
9	Heart septal defect	99.39%	L4	Proceed with Guardrails
10	Endemic goiter	99.34%	L5	Hold

Interpretation: 9 of 10 predictions involve congenital heart defects, which is highly consistent with alprostadil’s known pharmacology. Predictions ranked 1, 2, 5, and 9 have supporting literature. The endemic goiter prediction (rank 10) appears to be a false positive with no mechanistic basis.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alprostadil’s use in aortic malformations is already a well-established clinical practice in neonatal cardiology worldwide. The TxGNN prediction is mechanistically sound and supported by extensive clinical literature spanning over four decades. This represents a case of computational validation of existing off-label practice rather than a novel repurposing discovery. The lack of formal regulatory indication labelling for this specific use in the Netherlands presents an opportunity for label alignment with clinical reality.

To proceed, the following is needed:

Confirm current CBG-MEB/EMA marketing authorization status for alprostadil in the Netherlands (neonatal formulation)
Obtain the SmPC to complete the safety profile (key warnings, contraindications, drug interactions)
Retrieve detailed mechanism of action data from DrugBank to complete the pharmacological dossier
Conduct a systematic review of alprostadil use in aortic malformations to formally quantify efficacy and safety
Engage with paediatric cardiologists in the Netherlands to document current clinical practice patterns and any unmet regulatory needs

This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-03.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.